Levine Alan M

SEC source: 0000805928-26-000089 · wk-form4_1782507176.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000080 · wk-form4_1782247037.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000080 · wk-form4_1782247037.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-25-000097 · wk-form4_1750450070.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000085 · wk-form4_1749673609.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,743

F1 · acquired: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

SEC source: 0000805928-24-000119 · wk-form4_1725497924.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000119 · wk-form4_1725497924.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-24-000095 · wk-form4_1718057710.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000095 · wk-form4_1718057710.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,912

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-23-000110 · wf-form4_169408237644505.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,904

Underlying: Common Stock · 11,904 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000110 · wf-form4_169408237644505.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,436

Underlying: Common Stock · 20,436 shares

Expires 2033-09-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000068 · wf-form4_168600585210512.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,459 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.

SEC source: 0000805928-23-000068 · wf-form4_168600585210512.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,259

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 4

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 3

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000068 · wf-form4_165428729291275.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-21-000107 · wf-form4_162275467679419.xml · derivative · entry 4

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,036

Underlying: Common Stock · 3,036 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-21-000107 · wf-form4_162275467679419.xml · derivative · entry 3

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires 2031-06-01

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-21-000107 · wf-form4_162275467679419.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,173 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: This reflects the number of restricted stock units that became vested as of June 1, 2021.

F2 · derivative.expiration_date: This reflects the number of restricted stock units that became vested as of June 1, 2021.

SEC source: 0000805928-21-000107 · wf-form4_162275467679419.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-20-009633 · edgar.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,591

F1 · shares: This reflects the number of restricted stock unit that became vested as of September 3, 2020.

SEC source: 0001179110-20-007282 · edgar.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,173

Underlying: Common Stock · 6,173 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

SEC source: 0001179110-20-007282 · edgar.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,605

Underlying: Common Stock · 12,605 shares

Expires 2030-06-01

F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The updated beneficial holdings are being submitted in this Form 4/A.

SEC source: 0001179110-19-010128 · edgar.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,591

Underlying: Common Stock · 2,591 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-19-010128 · edgar.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,710

Underlying: Common Stock · 10,710 shares

Expires 2029-09-03

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-20-006915 · edgar.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,591

Underlying: Common Stock · 2,591 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-20-006915 · edgar.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,710

Underlying: Common Stock · 10,710 shares

Expires 2029-09-03

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001179110-19-006340 · edgar.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,933

Underlying: Common Stock · 23,933 shares

Expires 2022-05-15

F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest annually in equal parts over a three year period and become fully vested on May 15, 2022.